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JOURNAL OF HEPATOLOGYReply to: ‘‘Shunt dysfunction: Is it suitable as the primary end point
in transjugular intrahepatic portosystemic shunt trials?’’
To the Editor:
We are very honoured by the interest of Han and colleagues for
our study [1]. In their letter two topics were discussed. The ﬁrst
topic was the type of dysfunction in which they underlined and
illustrated the risk of initial stent malposition. The second topic
was in relation with the primary end point of our study. Here,
they suggested the use of clinical recurrence rather than haemo-
dynamics, to qualify shunt dysfunction.
Concerning the ﬁrst point, we noticed that stenoses were
mainly located at the upper end of the TIPS and at the hepatic
vein, with cumulative rates of 63.7% with covered stents and
70.5% with bare stents. A great majority of new stent insertion
and redilation procedures were performed at the ﬁrst six-month
scheduled control. This can effectively address an initial stent
malposition, as described in this interesting case by our Chinese
colleagues. This case report illustrates well how difﬁcult it is, dur-
ing the initial procedure, to adjust the upper side of the TIPS to
the vena cava. It is also difﬁcult to avoid the straightening of
the stent against the hepatic vein wall when withdrawing the
inside catheter. There is no reason why this problem would occur
with a certain type of stent and inﬂuence the results of our com-
parative trial. Furthermore, as our study was multi-centred, this
minimized the inﬂuence of operator dependent bias.
The second point is more disputable. In our study, the primary
end point was to compare short and long term patency of bare
and covered stents independently of their efﬁciency on symp-
toms. As the recurrence of symptoms, which was our secondary
end point, seldom occurred (twelve in all), it was not used as a
discriminator. Variable delay between haemodynamic dysfunc-
tion and clinical recurrence, severity of underlying cirrhosis, or
potential reversibility of some liver diseases explain that shunt
dysfunction and bleeding recurrence are not identical. Thus,
symptom recurrence may not occur despite the presence of shunt
dysfunction when the porto-caval gradient can be reduced after
alcohol withdrawal or virus clearance. Furthermore, we would
like to point out three arguments in favour of haemodynamic
criteria.
First, ascites recurrence does not expose patients to a death
risk, unlike variceal rebleeding. Rebleeding is observed in 20%
of cases with bare stents [2], and in 10% with covered stents.
These events have a proper mortality rate as described by other
teams [1,3–5], which can be estimated at 6% [6]. Waiting for a
symptom to occur is harmful in term of mortality. We have made
the choice to continue to detect shunt dysfunction as early as
possible especially for bleeding indications.
Second, the delay between shunt dysfunction and symptom
recurrence depends on so many parameters that it seems impos-
sible to anticipate. A TIPS which has been completely thrombosed
for a long time, can be technically difﬁcult to recanalize. Some-
times it is impossible and we need to perform a new TIPS besides
the old one. This is why then we prefer to detect and correct
dysfunction early before complete occlusion. The problem lies
in the early detection of shunt dysfunction and we agree with
Cai et al. that Doppler is not a conﬁdent method for screening.
In an ancillary study of STIC-TIPS (submitted paper) we compared
different Doppler parameters without ﬁnding a good sensitive
and speciﬁc marker of dysfunction. Perhaps, as suggested by Rös-
sle, a parameter combining endoscopy and Doppler could provide
this faithful alarm we need to detect TIPS dysfunction [7].
Third, we are not convinced that clinical criteria should
replace haemodynamic criteria in studies dedicated to TIPS in
general. To our knowledge, sensitivity and speciﬁcity of symptom
recurrence to diagnose impaired TIPS patency has not been stud-
ied previously and many confounding variables can interfere
with the diagnosis i.e.: ascites recurrence may be due to either
salt or water restriction modiﬁcation, diuretic variation, cardiac
or renal failure. For multicentre studies non-questionable criteria
are essential and haemodynamic parameters validate this condi-
tion in our opinion. Hepatic venous pressure gradient (HVPG) is
considered as the gold standard for portal hypertension measure-
ment. When Cai et al. checked the patency of their TIPS, they
observed a raise of the portosystemic pressure gradient to
16 mmHg.
Of course, studies exploring the efﬁcacy of TIPS upon different
complications of portal hypertension should have as end point
the clinical recurrence of the indication for TIPS. But we had a
different goal, which was to compare the patency of bare and
covered stents used to perform TIPS.
Finally, it may be important to discuss the need of a system-
atic angiographic TIPS control after 6 months (or earlier) to
correct malposition of the TIPS. Randomized studies about TIPS
treatment or conventional treatment of variceal bleeding or asci-
tes should always have recurrence of indication as a clinical end
point. Randomized controlled trials about methods to treat portal
Journal of Hepatology 2015 vol. 62 j 238–251 247
Open access under CC BY-NC-ND license.
hypertension should keep the portocaval gradient or HVPG as
primary end point and gold standard.
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A case of drug rash with eosinophilia and systemic symptoms (DRESS)
induced by telaprevir associated with HHV-6 active infection
To the Editor:
We read with interest the article by Samain and colleagues [1] on
the ‘‘First case of drug rash eosinophilia and systemic symptoms
due to boceprevir’’ and would like to report herein the ﬁrst case
of the same syndrome, following telaprevir treatment in associa-
tion with HHV-6 active infection in skin tissue.
DRESS is a severe adverse drug-induced reaction that mani-
fests as a diffuse maculo-papular skin rash with fever, haemato-
logical abnormalities (leukocytosis, eosinophilia and/or atypical
lymphocytosis) and multi-organ involvement, especially liver
dysfunction [2]. The exact pathogenesis of the syndrome remains
largely unknown but recently it has been associated with a T cell
immune response directed towards herpes virus antigens and/or
the culprit drug along with HHV-6 reactivation [3,4]. DRESS
patients appear to possess low numbers of plasmacytoid den-
dritic cells, a leukocyte subset producing large amount of IFN-a
and specialized in antiviral responses, allowing reactivation of
HHVs (like HHV-6) [4]. Therefore, telaprevir as a culprit drug
may trigger viral reactivations that induce a pathogenetic antivi-
ral CD8+ immune response [2].
Moreover, HHV-6 reactivation has been linked with a more
severe course of DRESS [4]. In a previously described case of tela-
previr-induced DRESS, HHV-6 infection was documented only
indirectly by a serological analysis (simply measuring elevation
of the anti-HHV-6 antibody titre) [5] and not in the plasma and
skin tissue, as it was detected in our patient. Sixteen other cases
of DRESS (3 deﬁnite, 5 probable and 8 possible) induced by tela-
previr [6–8] have been described from 2010 to date, but all with-
out mentioning HHV-6 reactivation.
A 51-year-old Caucasian woman with chronic genotype 1a
hepatitis C (viral load 1.8  106 IU/ml), complicated with ﬁbro-
sis (F-2 stage, measured by ultrasonographic elastography),
received treatment with the combination of interferon alfa-2a
(PegIFN) and ribavirin (RBV) for four weeks, without adverse
effect. Then telaprevir was added (2250 mg/daily) on April
2013 (day 0) in the absence of skin lesions. After three weeks
(day 24) from the telaprevir introduction, undetectable plasma
viraemia for HCV-ribonucleic acid (RNA) occurred and skin
manifestations as maculo-papular itchy lesions appeared on
the patient’s limbs. Oral antihistamines and topical steroids
were started with partial beneﬁt but after a few days the
patient worsened. Two weeks later, physical examination
revealed a diffuse maculo-papular exanthem, oro-pharyngeal
mucosa hyperaemia and bilateral painful axillar lymphadenopa-
thies associated with pruritus, fever (38 C), malaise and
arthralgia. Telaprevir was discontinued and oral prednisone
(0.5 mg/kg/daily) was promptly started. Cutaneous and systemic
symptoms improved in a few days, whereas the blood cells
count returned to normal within two weeks. Prednisone was
gradually decreased and stopped in one month.
Laboratory ﬁndings showed eosinophilia (white blood cell
count 5.10  109/L; eosinophils 19.8%, up to 1  109 cells/L) and
lymphocytopenia (7.2%, up to 0.40  109 cells/L). Antibodies
against cytomegalovirus (CMV), Epstein-Barr virus (EBV), and
adenovirus were indicative of past infection. Bacterial and fungal
culture of throat swab revealed a normal pharyngeal ﬂora.
Plasma HCV-RNA was persistently negative. Reactivation of
HHV-6 was demonstrated by detection of HHV-6 cell-free serum
viraemia (260 genome equivalents per ml). Anti-HHV-6 IgG
antibodies proved positive (titre 1/80), while anti-HHV-6 IgM
and anti-human herpes virus 7 (HHV-7) IgG and IgM antibodies
were negative. Active HHV-6 infection was demonstrated also
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